Medpace Holdings, Inc. (MEDP) Stock Analysis
Falling Knife setup · Temp Headwind edge
Healthcare · Diagnostics & Research
Hold if already holding. Not a fresh buy at $415.72, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Negative news sentiment (-0.60).
Medpace Holdings is a full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to biotechnology, pharmaceutical, and medical device companies globally, with ~6,200 employees across 46 countries. Revenue is generated from... Read more
Hold if already holding. Not a fresh buy at $415.72, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Negative news sentiment (-0.60). Chart setup: Death cross, below all MAs, RSI 32, MACD bearish. Maintain position. Not compelling to add more. Score 5.6/10, moderate confidence.
Passes 5/7 gates (clean insider activity, no SEC red flags, news events none recent, earnings proximity 81d clear, semi cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMCustomertop-10 customers35%10-K Item 1A: 'we derive approximately 35.1% of our net revenue from our top ten customers'
Material Events(8-K, last 90d)
- 2026-04-22Item 5.02MEDIUMJesse Geiger notified intent to resign as President and retire from the Company effective May 31, 2026. No reason beyond retirement cited. No successor named.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
1 floor-breaker
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $415.72, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Negative news sentiment (-0.60). Chart setup: Death cross, below all MAs, RSI 32, MACD bearish. Maintain position. Not compelling to add more. Target $520.35 (+25.2%), stop $386.03 (−7.7%), A.R:R -0.6:1. Score 5.6/10, moderate confidence.
Take-profit target: $520.35 (+25.4% upside). Target $520.35 (+25.2%), stop $386.03 (−7.7%), A.R:R -0.6:1. Stop-loss: $386.03.
Analyst target reached - limited upside remaining; Negative news sentiment (-0.60); Negative momentum.
Medpace Holdings, Inc. trades at a P/E of 26.0 (forward 22.3). TrendMatrix value score: 4.5/10. Verdict: Hold.
20 analysts cover MEDP with a consensus score of 3.6/5. Average price target: $443.
What does Medpace Holdings, Inc. do?Medpace Holdings is a full-service clinical contract research organization (CRO) providing Phase I-IV clinical...
Medpace Holdings is a full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to biotechnology, pharmaceutical, and medical device companies globally, with ~6,200 employees across 46 countries. Revenue is generated from fixed-fee and other contracts for services including trial management, biostatistics, regulatory affairs, and laboratory services; 82% of 2025 net revenue came from small biopharmaceutical companies.